- Home
- YYAI vs MTVA Comparison
YYAI vs MTVA Comparison
Compare YYAI & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYAI
- MTVA
- Stock Information
- Founded
- YYAI 2015
- MTVA 2014
- Country
- YYAI Hong Kong
- MTVA United States
- Employees
- YYAI N/A
- MTVA N/A
- Industry
- YYAI
- MTVA
- Sector
- YYAI
- MTVA
- Exchange
- YYAI NYSE
- MTVA NYSE
- Market Cap
- YYAI 13.7M
- MTVA 14.3M
- IPO Year
- YYAI N/A
- MTVA N/A
- Fundamental
- Price
- YYAI $0.89
- MTVA $0.66
- Analyst Decision
- YYAI
- MTVA Strong Buy
- Analyst Count
- YYAI 0
- MTVA 2
- Target Price
- YYAI N/A
- MTVA $7.50
- AVG Volume (30 Days)
- YYAI 186.5K
- MTVA 133.9K
- Earning Date
- YYAI 08-05-2025
- MTVA 08-13-2025
- Dividend Yield
- YYAI N/A
- MTVA N/A
- EPS Growth
- YYAI N/A
- MTVA N/A
- EPS
- YYAI N/A
- MTVA N/A
- Revenue
- YYAI N/A
- MTVA N/A
- Revenue This Year
- YYAI N/A
- MTVA N/A
- Revenue Next Year
- YYAI N/A
- MTVA N/A
- P/E Ratio
- YYAI N/A
- MTVA N/A
- Revenue Growth
- YYAI N/A
- MTVA N/A
- 52 Week Low
- YYAI $0.35
- MTVA $0.63
- 52 Week High
- YYAI $18.96
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- YYAI 51.78
- MTVA N/A
- Support Level
- YYAI $0.75
- MTVA N/A
- Resistance Level
- YYAI $0.92
- MTVA N/A
- Average True Range (ATR)
- YYAI 0.11
- MTVA 0.00
- MACD
- YYAI -0.00
- MTVA 0.00
- Stochastic Oscillator
- YYAI 33.33
- MTVA 0.00
About YYAI CONNEXA SPORTS TECHNOLOGIES IN
Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.